Pancreatic Cancer Research

ResearcherQueen Elizabeth HospitalActive in the last 2 years

William Chi Shing Cho

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4174-4586; OpenAlex author ID A5049313911. Sources: OpenAlex.

Their work

Papers
5 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
11
Papers, trials and grants by year

2021: 2 papers · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 5

  1. 20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transporters. Co-author DOI 10.1016/j.jare.2024.09.006↗
  2. The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies. Last author DOI 10.1016/j.biopha.2022.113364↗
  3. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway. Co-author DOI 10.1186/s13046-022-02270-z↗
  4. Quercetin Impact in Pancreatic Cancer: An Overview on Its Therapeutic Effects. Last author DOI 10.1155/2021/4393266↗
  5. Regulation of Hippo, TGFβ/SMAD, Wnt/β-Catenin, JAK/STAT, and NOTCH by Long Non-Coding RNAs in Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.657965↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hong‐Xi Xu · 2 shared papers, 2022–2025 · strength 0.44
  2. Yan‐Fang Xian · 2 shared papers, 2022–2025 · strength 0.44
  3. Juan Zhang · 2 shared papers, 2022–2025 · strength 0.44
  4. Zhi‐Xiu Lin · 2 shared papers, 2022–2025 · strength 0.44
  5. Yulin Wu · 1 shared paper, 2025 · strength 0.28
  6. Yang Li · 1 shared paper, 2022 · strength 0.16
  7. Maria Gazouli · 1 shared paper, 2021 · strength 0.15
  8. Rossana Berardi · 1 shared paper, 2021 · strength 0.15
  9. Ammad Ahmad Farooqı · 1 shared paper, 2021 · strength 0.15
  10. Monica Butnariu · 1 shared paper, 2022 · strength 0.12
  11. Parina Asgharian · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.